CBER, ORA Saw FY 2020 User Fee Spending Drop Even As COVID Strained US FDA’s Resources

 
• By Derrick Gingery

ORA continued to spend user fee dollars despite its inability to travel for facility inspections, while CBER found little generic and biosimilar work during FY 2020.

Financial management
The pandemic forced spending adjustments in several FDA offices during FY 2020. • Source: Alamy

More from User Fees

More from Pathways & Standards